FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2884390718> ?p ?o ?g. }

• W2884390718 endingPage "3567" @default.
• W2884390718 startingPage "3558" @default.
• W2884390718 abstract "Mutations in superoxide dismutase 1 (SOD1) are responsible for 20% of familial ALS. Given the gain of toxic function in this dominantly inherited disease, lowering SOD1 mRNA and protein is predicted to provide therapeutic benefit. An early generation antisense oligonucleotide (ASO) targeting SOD1 was identified and tested in a phase I human clinical trial, based on modest protection in animal models of SOD1 ALS. Although the clinical trial provided encouraging safety data, the drug was not advanced because there was progress in designing other, more potent ASOs for CNS application. We have developed next-generation SOD1 ASOs that more potently reduce SOD1 mRNA and protein and extend survival by more than 50 days in SOD1G93A rats and by almost 40 days in SOD1G93A mice. We demonstrated that the initial loss of compound muscle action potential in SOD1G93A mice is reversed after a single dose of SOD1 ASO. Furthermore, increases in serum phospho-neurofilament heavy chain levels, a promising biomarker for ALS, are stopped by SOD1 ASO therapy. These results define a highly potent, new SOD1 ASO ready for human clinical trial and suggest that at least some components of muscle response can be reversed by therapy." @default.
• W2884390718 created "2018-08-03" @default.
• W2884390718 creator A5007489515 @default.
• W2884390718 creator A5009098620 @default.
• W2884390718 creator A5011997502 @default.
• W2884390718 creator A5022227659 @default.
• W2884390718 creator A5022326820 @default.
• W2884390718 creator A5023765917 @default.
• W2884390718 creator A5028564265 @default.
• W2884390718 creator A5031167838 @default.
• W2884390718 creator A5033732336 @default.
• W2884390718 creator A5034350503 @default.
• W2884390718 creator A5044584675 @default.
• W2884390718 creator A5044923359 @default.
• W2884390718 creator A5046921947 @default.
• W2884390718 creator A5059691366 @default.
• W2884390718 creator A5068669762 @default.
• W2884390718 creator A5074623444 @default.
• W2884390718 creator A5082241391 @default.
• W2884390718 creator A5083296071 @default.
• W2884390718 creator A5084547304 @default.
• W2884390718 creator A5087337344 @default.
• W2884390718 creator A5087477950 @default.
• W2884390718 creator A5089795418 @default.
• W2884390718 creator A5091157375 @default.
• W2884390718 date "2018-07-16" @default.
• W2884390718 modified "2023-10-16" @default.
• W2884390718 title "Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models" @default.
• W2884390718 cites W143047277 @default.
• W2884390718 cites W1533702779 @default.
• W2884390718 cites W1927582128 @default.
• W2884390718 cites W1929098576 @default.
• W2884390718 cites W1980614738 @default.
• W2884390718 cites W1997188614 @default.
• W2884390718 cites W1999638129 @default.
• W2884390718 cites W2002104055 @default.
• W2884390718 cites W2013135033 @default.
• W2884390718 cites W2024118360 @default.
• W2884390718 cites W2030317956 @default.
• W2884390718 cites W2034445101 @default.
• W2884390718 cites W2045291659 @default.
• W2884390718 cites W2052578428 @default.
• W2884390718 cites W2054664888 @default.
• W2884390718 cites W2055062944 @default.
• W2884390718 cites W2062810043 @default.
• W2884390718 cites W2063996210 @default.
• W2884390718 cites W2065771915 @default.
• W2884390718 cites W2072978915 @default.
• W2884390718 cites W2073757903 @default.
• W2884390718 cites W2082705131 @default.
• W2884390718 cites W2107768418 @default.
• W2884390718 cites W2110603456 @default.
• W2884390718 cites W2125716259 @default.
• W2884390718 cites W2128739333 @default.
• W2884390718 cites W2128768698 @default.
• W2884390718 cites W2133408527 @default.
• W2884390718 cites W2141759311 @default.
• W2884390718 cites W2148337823 @default.
• W2884390718 cites W2149414920 @default.
• W2884390718 cites W2157076525 @default.
• W2884390718 cites W2158695265 @default.
• W2884390718 cites W2297831727 @default.
• W2884390718 cites W2338545563 @default.
• W2884390718 cites W2406449858 @default.
• W2884390718 cites W2411505396 @default.
• W2884390718 cites W2527286710 @default.
• W2884390718 cites W2582711285 @default.
• W2884390718 cites W2584936131 @default.
• W2884390718 cites W2592243741 @default.
• W2884390718 cites W2605681290 @default.
• W2884390718 cites W2765483614 @default.
• W2884390718 cites W2784384031 @default.
• W2884390718 doi "https://doi.org/10.1172/jci99081" @default.
• W2884390718 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6063493" @default.
• W2884390718 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30010620" @default.
• W2884390718 hasPublicationYear "2018" @default.
• W2884390718 type Work @default.
• W2884390718 sameAs 2884390718 @default.
• W2884390718 citedByCount "156" @default.
• W2884390718 countsByYear W28843907182018 @default.
• W2884390718 countsByYear W28843907182019 @default.
• W2884390718 countsByYear W28843907182020 @default.
• W2884390718 countsByYear W28843907182021 @default.
• W2884390718 countsByYear W28843907182022 @default.
• W2884390718 countsByYear W28843907182023 @default.
• W2884390718 crossrefType "journal-article" @default.
• W2884390718 hasAuthorship W2884390718A5007489515 @default.
• W2884390718 hasAuthorship W2884390718A5009098620 @default.
• W2884390718 hasAuthorship W2884390718A5011997502 @default.
• W2884390718 hasAuthorship W2884390718A5022227659 @default.
• W2884390718 hasAuthorship W2884390718A5022326820 @default.
• W2884390718 hasAuthorship W2884390718A5023765917 @default.
• W2884390718 hasAuthorship W2884390718A5028564265 @default.
• W2884390718 hasAuthorship W2884390718A5031167838 @default.
• W2884390718 hasAuthorship W2884390718A5033732336 @default.
• W2884390718 hasAuthorship W2884390718A5034350503 @default.
• W2884390718 hasAuthorship W2884390718A5044584675 @default.
• W2884390718 hasAuthorship W2884390718A5044923359 @default.

• next